![](https://www.fyonibio.com/wp-content/uploads/2021/07/Cover-FyoniBio-news-events.jpg)
News and Events
News From Inside
FyoniBio collaborates with BioLamina and Alder Therapeutics
![](https://www.fyonibio.com/wp-content/uploads/2024/02/Posting-Design_2-1024x683.jpg)
FyoniBio, Alder Therapeutics, and BioLamina enter Consortium Grant Agreement to Propel Recombinant Human Laminin Development for Clinical Applications.
FyoniBio gets CIR accreditation
![](https://www.fyonibio.com/wp-content/uploads/2024/02/Posting-CIR-300x200.jpg)
We are pleased to announce that FyoniBio has received CIR (Crédit d’Impôt Recherche or CIR) accreditation for three years until 2025, which will benefit our French clientele.
Launch of FyoniBio’s CHOFlow® Technology
![](https://www.fyonibio.com/wp-content/uploads/2023/05/Abbildung_News_CHO_Launch-1024x683.jpg)
CHOFlow®: Our high yield expression technology for afucosylated ADCC enhanced antibodies and beyond.
Successful Cell Line Development for Strike Pharma
![](https://www.fyonibio.com/wp-content/uploads/2023/05/Press_Release_Strike_small.jpg)
Strike Pharma and FyoniBio Conclude Successfully Cell Line Development of Strike’s Bi-specific Antibody and Clinical Lead Candidate.
Service Agreement with adivo
![](https://www.fyonibio.com/wp-content/uploads/2023/01/Posting-Kooperation_adivo_thumabnail.jpg)
FyoniBio and adivo GmbH sign a Service Agreement covering the generation of a production cell line for their canine therapeutic mAb candidate
Cooperation with Strike Pharma
![](https://www.fyonibio.com/wp-content/uploads/2022/10/PR-Strike-Pharma-1024x683.jpg)
We have signed a Master Service Agreement with Strike Pharma covering the cell line development for a novel bi-specific therapeutic mAb.
Partnership with ProteoNic
![](https://www.fyonibio.com/wp-content/uploads/2022/07/Pressrelease_-Proteonic_FyoniBio-1024x683.png)
We have signed a license agreement for using ProteoNic’s 2G Unic™ technology in our cell line development platform.
Launch of FyoniBio GmbH
![](https://www.fyonibio.com/wp-content/uploads/2022/01/FyoniBio_Logo_2zeilig-1024x512.png)
The FyoniBio service branch of Glycotope GmbH will continue its business as FyoniBio GmbH.
Cooperation with BioGenes
![](https://www.fyonibio.com/wp-content/uploads/2021/10/Biogenes2.png)
BioGenes and FyoniBio begin a cooperation for Pharmacokinetic & Immunogenicity Analyses
Collaboration with CSL Behring
![](https://www.fyonibio.com/wp-content/uploads/2022/03/News-CSLBehringFyoniBio2.png)
We are happy to have initiated a collaboration with CSL Behring research division.
Current and Upcoming Events
PEGS Boston 2024
![](https://www.fyonibio.com/wp-content/uploads/2024/04/PEGS-Boston-picture.jpeg)
Connect with FyoniBio at the PEGS Boston Summit in the USA! This conference is vital for streamlining biologics development, bringing together top experts in biologics innovation. Gain insights into the latest technologies, research, and advancements in drug development, protein and antibody engineering, immunotherapy, expression platforms, multispecific antibodies, machine learning, AI in biologics, and more.
13 – 17 May 2024
BIO International Convention 2024
![](https://www.fyonibio.com/wp-content/uploads/2024/05/Bio-Convention-picture-1024x535.png)
Meet FyoniBio at the BIO International Convention in San Diego, USA! This convention is the premier event for the biotechnology industry, bringing together over 20,000 leaders from around the world. It represents the entire biotech ecosystem, from public pharmaceutical companies and biotech startups to academia, non-profits, and government agencies.
3 – 6 June 2024
ESACT Meeting 2024
![](https://www.fyonibio.com/wp-content/uploads/2024/05/ESACT-picture.png)
Attend the 28th ESACT meeting, the premier event for professionals in the biotechnology and cell therapy industries. Organized by the European Society for Animal Cell Technology, ESACT brings together scientists, engineers, and specialists working with animal cells to foster communication and collaboration between European and international researchers.
23 – 26 June 2024